← Back to Clinical Trials
Recruiting NCT00404898

NCT00404898 NYU/Bellevue WTC Health Impacts Research Registry

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT00404898
Status Recruiting
Phase
Sponsor NYU Langone Health
Condition Exposure to World Trade Center Dust
Study Type OBSERVATIONAL
Enrollment 40,000 participants
Start Date 2007-12
Primary Completion 2026-09

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 40,000 participants in total. It began in 2007-12 with a primary completion date of 2026-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The American Red Cross has funded a multidisciplinary, comprehensive evaluation and treatment program for target individuals with suspected World Trade Center (WTC)-related health problems. The populations served consist predominantly of a) local residents who were impacted by the disperion of the WTC dusts and fumes, b) individuals involved in cleaning and debris removal of local commercial spaces, and c) responders to the WTC collapse. These populations are recruited from past and ongoing programs that we have developed as well as from ongoing collaborations with community organizations that include: the Beyond Ground Zero Network, 9/11 Environmental Action committee, and the WTC Residents Coalition. In addition, there is collaboration with the Charles B. Wang Community Health Center and the centers involved in the ongoing WTC Workers and Volunteer Medical Screening and Monitoring Program. We would now like to access the data from this treatment program to create a NYU/Bellevue WTC Health Impacts Research Registry to increase knowledge about the health effects of exposure to World Trade Center dust.

Eligibility Criteria

Target populations who will participate in the Bellevue Hospital Red Cross WTC Health Impacts Program will include: * residents (children and adults) of Lower Manhattan communities at the time of the attacks, who remained or returned to their homes soon after the attacks * individuals involved in debris removal in surrounding commercial and residential buildings, * individuals involved in rescue, recovery and debris removal who have been previously screened through the World Trade Center Worker and Volunteer Medical Screening Program and are in need of continued treatment.

Contact & Investigator

Central Contact

Joan Reibman, MD

✉ joan.reibman@nyulangone.org

📞 212-263-6479

Principal Investigator

Joan Reibman, MD

PRINCIPAL INVESTIGATOR

NYU Langone Health

Frequently Asked Questions

Who can join the NCT00404898 clinical trial?

This trial is open to participants of all sexes, studying Exposure to World Trade Center Dust. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT00404898 currently recruiting?

Yes, NCT00404898 is actively recruiting participants. Contact the research team at joan.reibman@nyulangone.org for enrollment information.

Where is the NCT00404898 trial being conducted?

This trial is being conducted at New York, United States.

Who is sponsoring the NCT00404898 clinical trial?

NCT00404898 is sponsored by NYU Langone Health. The principal investigator is Joan Reibman, MD at NYU Langone Health. The trial plans to enroll 40,000 participants.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology